These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19034329)

  • 21. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy.
    Semb AG; van Wissen S; Ueland T; Smilde T; Waehre T; Tripp MD; Frøland SS; Kastelein JJ; Gullestad L; Pedersen TR; Aukrust P; Stalenhoef AF
    J Am Coll Cardiol; 2003 Jan; 41(2):275-9. PubMed ID: 12535822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Men with lower HDL cholesterol levels have significant increment of soluble CD40 ligand and high-sensitivity CRP levels following the cessation of long-term clopidogrel therapy.
    Obradovic S; Djukanovic N; Todorovic Z; Markovic I; Zamaklar-Trifunovic D; Protic D; Ostojic M
    J Atheroscler Thromb; 2015; 22(3):284-92. PubMed ID: 25273829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atorvastatin effect on circulating and leukocyte-produced CD40 ligand concentrations in people with normal cholesterol levels: a pilot study.
    Zineh I; Welder GJ; DeBella AE; Arant CB; Wessel TR; Schofield RS
    Pharmacotherapy; 2006 Nov; 26(11):1572-7. PubMed ID: 17064201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
    J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble CD40 ligand, platelet surface CD40 ligand, and total platelet CD40 ligand in atrial fibrillation: relationship to soluble P-selectin, stroke risk factors, and risk factor intervention.
    Choudhury A; Chung I; Panja N; Patel J; Lip GYH
    Chest; 2008 Sep; 134(3):574-581. PubMed ID: 18641098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated circulating levels of soluble CD-40 ligand in haemodialysis patients with symptomatic coronary heart disease.
    Lim PS; Wu MY; Chien SW; Wu TK; Liu CS; Hu CY; Chang HC; Pai MA
    Nephrology (Carlton); 2008 Dec; 13(8):677-83. PubMed ID: 19019166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets.
    Kappelle PJ; Dallinga-Thie GM; Dullaart RP;
    Biochim Biophys Acta; 2010 Jan; 1801(1):89-94. PubMed ID: 19800983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of high-dose atorvastatin on the cardiovascular risk associated with individual components of metabolic syndrome: a subanalysis of the Treating to New Targets (TNT) study.
    Deedwania PC; Shepherd J; Breazna A; DeMicco DA;
    Diabetes Obes Metab; 2016 Jan; 18(1):56-63. PubMed ID: 26434404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol.
    Kanadaşi M; Cayli M; Demirtaş M; Inal T; Demir M; Koç M; Avkaroğullari M; Dönmez Y; Usal A; Alhan CC; San M
    Heart Vessels; 2006 Sep; 21(5):291-7. PubMed ID: 17151816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-term effects of atorvastatin on C-reactive protein.
    Riesen WF; Engler H; Risch M; Korte W; Noseda G
    Eur Heart J; 2002 May; 23(10):794-9. PubMed ID: 12009719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study.
    Martineau P; Gaw A; de Teresa E; Farsang C; Gensini GF; Leiter LA; Langer A;
    Atherosclerosis; 2007 Mar; 191(1):135-46. PubMed ID: 16643923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
    N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atorvastatin affects C-reactive protein levels in patients with coronary artery disease.
    Karaca I; Ilkay E; Akbulut M; Yavuzkir M; Pekdemir M; Akbulut H; Arslan N
    Curr Med Res Opin; 2003; 19(3):187-91. PubMed ID: 12803732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
    Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D
    Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relationship between soluble CD40 ligand levels and Framingham coronary heart disease risk score in healthy volunteers.
    Verma S; Wang CH; Li SH; Lonn E; Charbonneau F; Title LM; Anderson TJ;
    Atherosclerosis; 2005 Oct; 182(2):361-5. PubMed ID: 16159609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of garlic powder on C-reactive protein and plasma lipids in overweight and smoking subjects.
    van Doorn MB; Espirito Santo SM; Meijer P; Kamerling IM; Schoemaker RC; Dirsch V; Vollmar A; Haffner T; Gebhardt R; Cohen AF; Princen HM; Burggraaf J
    Am J Clin Nutr; 2006 Dec; 84(6):1324-9. PubMed ID: 17158412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Markers of inflammation and platelet aggregation in patients with non ST elevation acute coronary syndrome treated with atorvastatin or pravastatin].
    Pokrovskaia EV; Vaulin NA; Gratsianskiĭ NA; Averkov OV; Deev AD
    Kardiologiia; 2003; 43(1):7-18. PubMed ID: 12891281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.